Valeant Pharmaceuticals - PDFSEARCH.IO - Document Search Engine

Valeant Pharmaceuticals
Results: 93

#	Item
71	An Unrivaled Platform for Growth & Value Creation in Healthcare Valeant Pharmaceuticals International, Inc. + Allergan, Inc. June 17, 2014 Add to Reading List Source URL: www.valeant.com Language: English - Date: 2014-06-18 08:52:21 Valeant Pharmaceuticals Allergan Finance Proxy statement Forward-looking statement Mergers and acquisitions Financial statement Business SEC filings Companies listed on the New York Stock Exchange
72	Investor Presentation Regarding the Allergan Special Meeting Process July 18, 2014 1 Add to Reading List Source URL: www.valeant.com Language: English - Date: 2014-07-18 08:37:21 Generally accepted accounting principles Mergers and acquisitions Valeant Pharmaceuticals Proxy statement Research and development Finance SEC filings Business Allergan
73	Clarification on assertions made about Valeant’s business (August 19) Forward-looking Statements This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Add to Reading List Source URL: www.valeant.com Language: English - Date: 2014-08-19 10:42:49 Bausch & Lomb Mergers and acquisitions Business Companies listed on the New York Stock Exchange Valeant Pharmaceuticals Allergan
74	An Unrivaled Platform for Growth & Value Creation in Healthcare Valeant Pharmaceuticals International, Inc. + Allergan, Inc. Add to Reading List Source URL: www.valeant.com Language: English - Date: 2014-04-28 13:34:06 Valeant Pharmaceuticals Proxy statement Mergers and acquisitions J. Michael Pearson Forward-looking statement Schedule 13D SEC filings Business Allergan
75	ACE BOWNE OF NEW YORK[removed]:03 NO MARKS Add to Reading List Source URL: www.valeant.com Language: English - Date: 2012-03-27 10:07:02 Business Companies listed on the New York Stock Exchange Valeant Pharmaceuticals Biovail SEC filings Corporate finance Proxy statement Mergers and acquisitions Dividend Stock market Financial economics Investment
76	1.375% Convertible Senior Notes due[removed]the “2017 Notes”) Issued by Medicis Pharmaceutical Corporation (“Medicis”) On December 11, 2012, Valeant Pharmaceuticals International, Inc. completed its acquisition of Add to Reading List Source URL: www.valeant.com Language: English - Date: 2012-12-11 11:02:54 Adjustment Conversion Religious conversion
77	2.5% Contingent Convertible Senior Notes due[removed]the “2032 Notes) Issued by Medicis Pharmaceutical Corporation (“Medicis”) On December 11, 2012, Valeant Pharmaceuticals International, Inc. completed its acquisiti Add to Reading List Source URL: www.valeant.com Language: English - Date: 2012-12-11 11:12:49 Mergers and acquisitions Business Companies listed on the New York Stock Exchange Medicis Pharmaceutical Conversion
78	Microsoft Word - AGN Ex Parte Application for Expedited Schedule(5824147_22_SF) (3).docx Add to Reading List Source URL: blogs.reuters.com Language: English - Date: 2014-08-07 16:04:37 Allergan Valeant Pharmaceuticals
79	The Police Retirement System of St. Louis v. Allergan, Inc., et al., C.A. No. 9675-, compl. (Del. Ch. May 20, 2014) EFiled: May[removed]:59PI$^t$> Transaction ID[removed]f%Sg$P) Case No[removed]vMSM^I Add to Reading List Source URL: blogs.reuters.com Language: English - Date: 2014-06-18 03:09:55 Private law Grant & Eisenhofer P.A. Valeant Pharmaceuticals Board of directors Law Business Corporations law Allergan
80	Microsoft Word - 1795793_17.doc Add to Reading List Source URL: blogs.reuters.com Language: English - Date: 2014-08-01 11:59:25 Pershing Square Capital Management Bill Ackman Lawsuit Tender offer Williams Act Investment Finance Financial economics Companies listed on the New York Stock Exchange Valeant Pharmaceuticals Allergan

UPDATE